Prospective long-term study on primary CMV infections in adult liver transplant (D+/R?) patients after valganciclovir prophylaxis |
| |
| Institution: | 1. School of Mechanical and Aerospace Engineering, Nanyang Technological University, 50 Nanyang Avenue, 639798, Singapore;2. Institute of Materials Research and Engineering, Agency for Science, Technology and Research (A*STAR), 2 Fusionopolis Way, Innovis, #08-03, 138634, Singapore;3. Energy Research Institute @ NTU, Interdisciplinary Graduate School, Nanyang Technological University, 50 Nanyang Avenue, 639798, Singapore;1. Division of Pulmonary, Critical Care and Sleep Medicine, Mount Sinai University, New York, NY;2. Department of Internal Medicine, Mercy Catholic Medical Center, Philadelphia, PA;3. Division of Pulmonary, Allergy and Critical Care Medicine, Emory University, Atlanta, GA;4. Pulmonary Medicine, Department of Veterans Affairs Medical Center, Atlanta, GA |
| |
| Abstract: | BackgroundCytomegalovirus (CMV) can cause severe infections in transplanted patients. To prevent CMV infection, most liver centers use prophylaxis for CMV-seronegative recipients receiving an organ from a seropositive donor (D+/R?). Valganciclovir is mostly given for 3–6 months after transplantation. However, the patients may develop primary CMV infection after the cessation of prophylaxis and late-onset CMV disease may occur.ObjectivesA prospective long-term follow-up of CMV (D+/R?) adult liver transplant recipients after 3 months valganciclovir prophylaxis was investigated.Study designOf 154 consecutive adult liver recipients transplanted from 2006 to 2009, 20 (13%) were CMV D+/R? and received antiviral prophylaxis up to 3 months after transplantation. After excluding the recipients with incomplete prophylaxis or monitoring, 13 (D+/R?) patients with follow-up of >4 years after the 3-month period of valganciclovir prophylaxis were included in the study.The patients were monitored for CMV by real-time quantitative plasma PCR.ResultsNo break-through CMV infections were recorded during the prophylaxis period. After cessation of valganciclovir prophylaxis 12/13 (90%) patients demonstrated CMV-DNAemia following a post transplantation mean interval of 165 days (range 95–320). Ten patients with high viral loads (peak viral load mean 81,510, range 1900–648950 cps/ml) were successfully treated, 6 with valganciclovir, and 4 with ganciclovir. Two patients with low level CMV-DNAemia (<1000 cps/ml) were asymptomatic and not treated. No intragraft infection was seen, but one patient developed gastrointestinal CMV infection verified from ileum biopsy. During long-term follow-up, 3 patients demonstrated low-level viral replication, but no symptomatic recurrences occurred. One patient died of bacterial sepsis, but no patient or graft was lost due to CMV.ConclusionsPrimary CMV infections after cessation of prophylaxis were common, but were successfully treated with valganciclovir or ganciclovir. |
| |
| Keywords: | Valganciclovir prophylaxis Liver transplantation |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
